Oral Bioavailability: Issues and Solutions via Nanoformulations

Clinical Pharmacokinetics

Volumn 54, Issue 4, 2015, Pages 325-357

  Pathak, Kamla ^a   Raghuvanshi, Smita ^a  

^a Rajiv Academy for Pharmacy ^*  (India)

Author keywords

[No Author keywords available]

Indexed keywords

APREPITANT; CARBON NANOTUBE; COLESEVELAM; CURCUMIN; DENDRIMER; DEXMETHYLPHENIDATE; FENOFIBRATE; FERUMOXSIL; GRISEOFULVIN; IBUPROFEN; ISONIAZID; ITRACONAZOLE; MEBENDAZOLE; MEGESTROL ACETATE; METHYLPHENIDATE; METOPROLOL; MORPHINE SULFATE; NANOCARRIER; NANOCRYSTAL; NANOPARTICLE; PACLITAXEL; PENETRATION ENHANCING AGENT; POLYMER; PROPRANOLOL; RAPAMYCIN; RIFAMPICIN; SEVELAMER; SOLID LIPID NANOPARTICLE; UNINDEXED DRUG; ZANAMIVIR; DRUG; DRUG CARRIER;

AREA UNDER THE CURVE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; DRUG SOLUBILITY; DRUG SOLUTION; ENZYMATIC DEGRADATION; FIRST PASS EFFECT; FOOD INTAKE; HUMAN; MICELLE; MICROCAPSULE; MOLECULAR WEIGHT; NANOEMULSION; NANOMEDICINE; NANOTECHNOLOGY; NONHUMAN; PARTITION COEFFICIENT; PATENT; PRIORITY JOURNAL; REVIEW; STOMACH EMPTYING; ANIMAL; BIOAVAILABILITY; DRUG DESIGN; METABOLISM; ORAL DRUG ADMINISTRATION; PROCEDURES;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; NANOPARTICLES; PHARMACEUTICAL PREPARATIONS; POLYMERS;

EID: 84925460778     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-015-0242-x     Document Type: Review

References (283)

1. Lavelle EC, Sharif S, Thomas NW, Holand J, Davis SS. The importance of gastrointestinal uptake of particles in the design of oral delivery systems. Adv Drug Deliv Rev. 1995;18:5–22.
2. Daugherty AL, Mrsny RJ. Regulation of the intestinal epithelial paracellular barrier. Pharm Sci Technol Today. 1999;2:144–51.
3. Thakkar H, Patel B, Thakkar S. A review on techniques for oral bioavailability enhancement of drugs. Int J Pharm Sci Rev Res. 2010;4:203–23.
4. US Food and Drug Administration. Code of federal regulation. Title 21, volume 5, chapter 1, subchapter D, part 320. Bioavailability and bioequivalence reagents.
5. Badawy SIF, Ghorab MM, Adeyeye CM. Characterization and bioavailability of danazolhydroxypropyl-β-cyclodextrin coprecipitates. Int J Pharm. 1996;128:45–54.
6. Borin MT, Ayres JW. Single dose bioavailability of acetoaminophen following oral administration. Int J Pharm. 1989;54:199–209.
7. Chen H, Khemtong C, Yang X, Chang X, Gao J. Nanonization strategies for poorly water-soluble drugs. Drug Discov Today. 2010;1–7.
8. Riehemann K, Schneider SW, Luger TA, Godin B, Ferrari M, Fuchs H. Nanomedicine—challenge and perspectives. Angew Chem Int Ed Engl. 2009;48:872–97.
9. Doherty MM, Pang KS. First-pass effect: significance of the intestine for absorption and metabolism. Drug Chem Toxicol. 1997;20:329–44.
10. Gertz M, Harrison A, Houston JB, Galetin A. Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. Drug Metab Depos. 2010;38:1147–58.
11. Arora S, Ali J, Ahuja A, Khar RK, Baboota S. Floating drug delivery systems: a review. AAPS Pharm Sci Tech. 2005;6:E372–90.
12. Soppimath KS, Kulkarni AR, Kukulkarni AR, Rudzinski WE, Aminabhavi TM. Microspheres as floating drug-delivery systems to increase gastric retention of drugs. Drug Metab Rev. 2001;33:149–60.
13. Gholap SB, Banariee SK, Gaikwad DD, Jadhav SL, Thorat RM. Hollow microspheres: a review. Int J Pharm Sci Rev Res. 2010;1:74–9.
14. Hirtz J. The gastrointestinal absorption of drugs in man: a review of current concepts and methods of investigation. Br J Clin Pharmacol. 1985;19:17S–83S.
15. Goyel M, Prajapati R, Purohit KK, Mehta SC. Floating drug delivery system. J Curr Pharm Res. 2011;5:7–18.
16. Singh BN, Kim KH. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J Control Release. 2000;63:235–59.
17. Nayak AK, Maji R, Das B. Gastroretentive drug delivery systems: a review. Asian J Pharm Clin Res. 2010;3:1–10.
18. Mullertz A. Oral drug absorption, 2nd edn. Ebook;2010.
19. Melander A. Influence of food on the bioavailability of drugs. Clin Pharmacokinet. 1978;3(5):337–51.
20. Winstanley PA, Orme LE. The effect of food on drug bioavailability. Br J Clin Pharmacol. 1989;28:621–8.
21. Cebrian MJC, Zornoza T, Granero L, Polache A. Intestinal absorption enhancement via paracellular route by fatty acids, chitosans and other: a target for drug delivery. Curr Drug Deliv. 2005;2:9–22.
22. Stenberg P, Luthaman K, Artursson P. Virtual screening of intestinal drug permeability. J Control Release. 2000;65:231–43.
23. 2 resorption. Science. 1999;285:103–6.
24. Werle M, Samhaber A, Bernkop-Schnurch A. Degradation of teriparatide by gastro-intestinal proteolytic enzymes. J Drug Target. 2006;14:109–15.
25. Svenson S, Chauhan AS. Dendrimers for enhanced drug solubilization. Nanomedicine. 2008;3(5):679–702.
26. Lipinski CA. Drug like properties and the cause of poor solubility and poor permeability. J Pharmacol Toxicol Methods. 2000;44:235–49.
27. Lindenberg M, Kopp S, Dressman JB. Classification of orally administered drugs on the World Health Organization model list of essential medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm. 2004;58:265–78.
28. Veber DF, Johnson SR, Cheng H, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002;45(12):2615–23.
29. Ungell AL, Nylander S, Bergstrand S, Sjönerg A, Lennernäs H. Membrane transport of drugs in different regions of the intestinal tract of the rat. J Pharm Sci. 1998;87:360–6.
30. Vemulapalli V, Khan NM, Jasti B. Physicochemical characteristics that influence the transport of drugs across intestinal barrier. AAPS News Mag. 2007:18–21.
31. Rasheed A, Kumar CK, Sravanthi VNSS. Cyclodextrins as drug carrier molecule: a review. Sci Pharm. 2008;76:567–98.
32. Farh A, Liu X. Drug delivery strategies for poorly water soluble drugs. Expert Opin Drug Deliv. 2007;4:403–16.
33. Mehramizi A, Monfared AE, Pourfarzib M, Bayati KH, Dorkoosh FA, Rafiee T. Influence of β-cyclodextrin complexation on lovastatin release from osmotic pump tablets (OPT). DARU. 2007;15(2):71–8.
34. Loftsson T, Masson M. Cyclodextrins in topical drug formulations: theory and practice. Int J Pharm. 2001;225:15–30.
35. Ueda H, Ou D, Endo T, Nagase H, Tomono K, Nagai T. Evaluation of a sulfobutyl ether beta-cyclodextrin as a solubilizing/stabilizing agent for several drugs. Drug Dev Ind Pharm. 1998;24:863–7.
36. Li J, Guo Y, Zografi G. The solid-state stability of amorphous quinapril in the presence of βCD. J Pharm Sci. 2002;91:229–43.
37. Szejtli J. Cyclodextrins and their inclusion complexes. Starch. 1982. doi:10.1002/star.19820341113.
38. Uekama K, Otagiri M. Drug carrier system—a review. Crit Rev Ther Drug Care Syst. 1987;3:1–12.
39. Mayur CA. Senthikumaran. Cyclodextrin in drug delivery: a review. Res Rev J Pharm Pharm Sci. 2012;1(1):19–29.
40. Sekiguchi K, Obi N. Studies on absorption of eutectic mixture: I. A comparison of the behavior of eutectic mixture of sulfathiazole and that of ordinary sulfathiazole in man. Chem Pharm Bull. 1961;9:866–72.
41. Goldberg AH, Galbaldi M, Kanig KL. Increasing dissolution rates and gastrointestinal absorption of drugs via solid solutions and eutectic mixtures III. Experimental evaluation of griseofulvin-succinic acid solution. J Pharm Sci. 1966;55:487–92.
42. Serajuddin ATM. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J Pharm Sci. 1999;88:1058–66.
43. Sharma A, Jain CP. Solid dispersion: a promising technique to enhance solubility of poorly water soluble drug. Int J Drug Deliv. 2011;3:149–70.
44. Khandare JJ, Chandna P, Wang Y, Pozharov VP, Minko T. Novel polymeric prodrug with multivalent component for cancer therapy. J Pharmacol Exp Ther. 2006;317(3):929–37.
45. Philip AK, Philip B. Colon targeted drug delivery systems: a review on primary and novel approaches. Oman Med J. 2010. doi:10.5001/omj.2010.24.
46. Tiwari G, Tiwari R, Pranay W, Wal A, Rai AK. Primary and novel approaches for colon targeted drug delivery: a review. Int J Drug Deliv. 2010;2:1–11.
47. Junginger HE. Polymeric permeation enhancers. Oral Deliv Macromol Drugs. 2009. doi:10.1007/978-1-4419-0200-9_6.
48. Singh N, Gupta P, Bhattacharyya A. Enhancement of intestinal absorption of poorly absorbed ceftriaxone sodium by using mixed micelles of polyoxy ethylene (20) cetyl ether & oleic acid as peroral absorption enhancers. Arch Appl Sci Res. 2010;2(3):131–42.
49. Whitehead K, Karr N, Mitragotri S. Safe and effective permeation enhancers for oral drug delivery. Pharm Res. 2007. doi:10.1007/s11095-007-9488-9.
50. Chauhan NS, Alam S, Mittal A, Bajaj U. A description on study of intestinal barrier, drug permeability and permeation enhancers. Int J Clin Pharmacol Toxicol. 2013;2:501.
51. Holmes EH, Devalapally H, Li L, Perdue ML, Ostrander GK. Permeability enhancers dramatically increase zanamivir absolute bioavailability in rats: implications for an orally bioavailable influenza treatment. PLoS One. 2013;8:1–7.
52. Gupta V, Hwang BH, Doshi N, Mitragotri S. A permeation enhancer for increasing transport of therapeutic macromolecules across the intestine. J Control Release. 2013;172(2):541–9.
53. Bansode SS, Banarjee SK, Gaikwad DD, Jadhav SL, Thorat RM. Microencapsulation: a review. Int J Pharm Sci Rev Res. 2010;1:38–43.
54. Singh MN, Hemant KSY, Shivakumar HG. Microencapsulation: a promising technique for controlled drug delivery. Res Pharm Sci. 2010;5(2):65–77.
55. Siepmann J, Siepmann F. Microparticles used as drug delivery systems. Prog Coll Pol Sci. 2006;133:15–21.
56. Padalkar AN, Sadhana R, Shahi SR. Microparticles: an approach for betterment of drug delivery system. Int J Pharma Res Dev. 2011;3:99–115.
57. Upadhyay MS, Pathak K. Glyceryl monooleate-coated bioadhesive hollow microspheres of riboflavin for improved gastroretentivity: optimization and pharmacokinetics. Drug Deliv Transl Res. 2013;3:209–23.
58. Srivastava R, Kumar D, Pathak K. Colonic luminal surface retentive meloxicam microsponges delivered by erosion based colon targeted matrix tablet. Int J Pharm. 2012;427:156–62.
59. Arya P, Pathak K. Assessing the viability of microsponges as gastro retentive drug delivery system of curcumin: optimization and pharmacokinetics. Int J Pharm. 2014;460:1–12.
60. Sigfridsson K, Nordmark A, Theilig S, Lindahl A. A formulation comparison between micro- and nanosuspensions: the importance of particle size for absorption of a model compound, following repeated oral administration to rats during early development. Drug Dev Ind Pharm. 2011;37(2):185–92.
61. Sahoo SK, Dilnawaz F, Krishnakumar S. Nanotechnology in ocular drug delivery. Drug Discov Today. 2008;13(3–4):144–51.
62. Muller RH, Gohla S, Keck CM. State of the art of nanocrystals—special features, production, nanotoxicology aspects and intracellular delivery. Eur J Pharm Biopharm. 2011;78:1–9.
63. Nasimi P, Haidari M. Medical use of nanoparticles drug delivery and diagnosis diseases. Int J Green Nanotechnol. 2013. doi:10.1177/1943089213506978.
64. Junghanns JUAH, Muller RH. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomed. 2008;3:295–309.
65. Pawar VK, Yuvraj Singh Y, Meher JG, Gupta S, Chourasia MK. Engineered nanocrystal technology: in-vivo fate, targeting and applications in drug delivery. J Control Release. 2014;183:51–66.
66. Müller RH, Shegokar R, Gohla S, Keck CM. Nanocrystals: production, cellular drug delivery, current and future products. Fund Biomed Technol. 2011;5:411–32.
67. Shegokar R, Müller RH. Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives. Int J Pharm. 2010;399(1–2):129–39.
68. Song J, Wang Y, Song Y, Chan H, Bi C, Yang X, et al. Development and characterisation of ursolic acid nanocrystals without stabiliser having improved dissolution rate and in vitro anticancer activity. AAPS PharmSciTech. 2014. doi:10.1208/s12249-013-0028-0.
69. Moeschwitzer J. Nanotechnology: particle size reduction technologies in the pharmaceutical development process. Am Pharm Rev. 2010;54–59.
70. Wu L, Zhang J, Watanabe W. Physical and chemical stability of drug nanoparticles. Adv Drug Deliv Rev. 2011;63:456–469. doi:10.1016/j.addr.2011.02.001.
71. Keck CM, Muller RH. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm. 2006;62:3–16.
72. Chan HK, Kwok PC. Production methods for nanodrug particles using the bottom-up approach. Adv Drug Deliv Rev. 2011;63(6):406–16.
73. Li Y, Yue PF, Hu PY, Wu ZF, Yang M, Yuan HL. A novel high-pressure precipitation tandem homogenization technology for drug nanocrystals production—a case study with ursodeoxycholic acid. Pharm Dev Technol. 2014;19(6):662–70.
74. Zhang H, Hollis CP, Zhang Q, Li T. Preparation and antitumor study of camptothecin nanocrystals. Int J Pharm. 2011;415(1–2):293–300.
75. Sinha B, Müller RH, Möschwitzer JP. Systematic investigation of the cavi-precipitation process for the production of ibuprofen nanocrystals. Int J Pharm. 2013;458(2):315–23.
76. ® is not realized in in vivo drug absorption. J Control Release. 2014;180:109–16.
77. Mou D, Chen H, Wan J, Xu H, Yang X. Potent dried drug nanosuspensions for oral bioavailability enhancement of poorly soluble drugs with pH-dependent solubility. Int J Pharm. 2011;413(1–2):237–44.
78. Patel K, Patil A, Mehta M, Gota V, Vavia P. Oral delivery of paclitaxel nanocrystal (PNC) with a dual Pgp-CYP3A4 inhibitor: preparation, characterization and antitumor activity. Int J Pharm. 2014;472(1–2):214–23.
79. Xia D, Quan P, Piao H, Piao H, Sun S, Yin Y, et al. Preparation of stable nitrendipine nanosuspensions using the precipitation–ultrasonication method for enhancement of dissolution and oral bioavailability. Eur J Pharm Sci. 2010;40:325–34.
80. Mohanty C, Sahoo SK. The in vitro stability and in vivo pharmacokinetics of curcumin prepared as an aqueous nanoparticulate formulation. Biomaterials. 2010;31:6597–611.
81. Zhao L, Feng SS. Enhanced oral bioavailability of paclitaxel formulated in vitamin E-TPGS emulsified nanoparticles of biodegradable polymers: in vitro and in vivo studies. J Pharm Sci. 2010;99(8):3552–60.
82. Onoue S, Takahashi H, Kawabata Y, Seto Y, Hatanaka J, Timmermann B, et al. Formulation design and photochemical studies on nanocrystal solid dispersion of curcumin with improved oral bioavailability. J Pharm Sci. 2010;99(4):1871–81.
83. Zhang J, Lv H, Jiang K, Gao Y. Enhanced bioavailability after oral and pulmonary administration of baicalein nanocrystal. Int J Pharm. 2011;420(1):180–8.
84. Jiang T, Han N, Zhao B, Xie Y, Wang S. Enhanced dissolution rate and oral bioavailability of simvastatin nanocrystal prepared by sonoprecipitation. Drug Dev Ind Pharm. 2012;38(10):1230–9.
85. Thadkala K, Nanam PK, Aukunuru J. Preparation and characterization of amorphous ezetimibe nanosuspensions intended for enhancement of oral bioavailability. Int.J Pharm Investig. 2014;4(3):131–37.
86. Shi-Ying J, Jin H, Shi-Xiao J, Qing-Yuan L, Jin-Xia B, Chen HG. Characterization and evaluation in vivo of baicalin-nanocrystals prepared by an ultrasonic-homogenization-fluid bed drying method. Chin J Nat Med. 2014;12(1):71–80.
87. Luo C, Yan L, Sun J, Zhang Y, Chen Q, Liu X, He Z. Felodipine nanosuspension: a faster dissolution rate and higher oral absorption efficiency. J Drug Del Sci Technol. 2014;24(2):173–7.
88. Borhade V, Pathak S, Sharma S, Patravale V. Formulation and characterization of atovaquone nanosuspension for improved oral delivery in the treatment of malaria. Nanomed (Lond). 2014;9(5):649–66.
89. Fu Q, Sun J, Zhang D, Li M, Wang Y, Ling G. Nimodipine nanocrystals for oral bioavailability improvement: preparation, characterization and pharmacokinetic studies. Colloids Surf B Biointerfaces. 2013;109:161–6.
90. Ige PP, Baria RK, Gattani SG. Fabrication of fenofibrate nanocrystals by probe sonication method for enhancement of dissolution rate and oral bioavailability. Colloids Surf B Biointerfaces. 2013;108:366–73.
91. Ravichandran R. Pharmacokinetic study of nanoparticulate curcumin: oral formulation for enhanced bioavailability. J Biomat Nanobiotechnol. 2013;4:291–9.
92. Quan P, Xia D, Piao H, Piao H, Shi K, Jia Y, et al. Nitrendipine nanocrystals: its preparation, characterization, and in vitro–in vivo evaluation. AAPS PharmSciTech. 2011;12(4):1136–43.
93. Ravichandran R. In vivo pharmacokinetic studies of albendazole nanoparticulate oral formulations for improved bioavailability. Int J Green Nanotech Biomed. 2010. doi:10.1080/1943085x.2010.488200.
94. Shah M, Chuttani K, Mishra AK, Pathak K. Oral solid Compritol 888 ATO nanosuspension of simvastatin: optimization and biodistribution studies. Drug Dev Ind Pharm. 2011;37(5):526–37.
95. Pokharkar VB, Malhi T, Mandpe L. Bicalutamide nanocrystal with improved oral bioavailability: in vitro and in vivo evaluation. Pharm Dev Technol. 2013. doi:10.3109/10837450.2012.663391.
96. Gao F, Zhang Z, Bu H, Huang Y, Gao Z, Shen J. Nanoemulsion improves the oral absorption of candesartan cilexetil in rats: performance and mechanism. J Control Release. 2011;149:68–74.
97. Landfester K, Willert M, Antonietti M. Preparation of polymer particles in nonaqueous direct and inverse miniemulsions. Macromolecules. 2000;33(7):2370–6.
98. Usón N, García MJ, Solans C. Formation of water-in-oil (w/o) nano-emulsions in a water/mixed non-ionic surfactant/oil systems prepared by a low-energy emulsification method. Colloid Surf A Physicochem Eng Asp. 2004;250:415–21.
99. Morales D, Gutiérrez JM, Garcia-Celma JM, Solans C. A study of the relation between bicontinuous microemulsions and oil/water nanoemulsion formation. Langmuir. 2003;19:7196–200.
100. Laouini A, Fessi H, Charcosset C. Membrane emulsification: a promising alternative for vitamin E encapsulation within nano-emulsion. J Membrane Sci. 2012;423–424:85–96.
101. Gorain B, Choudhury H, Kundu A, Sarkar L, Karmakar S, Jaisankar P, Pal TP. Nanoemulsion strategy for olmesartan medoxomil improves oral absorption and extended antihypertensive activity inhypertensive rats. Colloid Surf B. 2014;115:286–94.
102. Singh S, Kamla Pathak K, Bali V. Product development studies on surface-adsorbed nanoemulsion of olmesartan medoxomil as a capsular dosage form. AAPS PharmSciTech. 2012;13:1212–21.
103. Devalapally H, Silchenko S, Zhou F, Owen A, Hidalgo IJ. Evaluation of a nanoemulsion formulation strategy for oral bioavailability enhancement of danazol in rats and dogs. J Pharm Sci. 2013;102(10):3808–15.
104. Chavhan SS, Petkar KC, Sawant KK. Simvastatin nanoemulsion for improved oral delivery: design, characterisation, in vitro and in vivo studies. J Microencapsul. 2013;30(8):771–9.
105. Belhaj N, Dupuis F, Tehrany EA, Denis FD, Paris C, Lartaud I, et al. Formulation, characterization and pharmacokinetic studies of coenzyme Q10 PUFA’s nanoemulsions. Eur J Pharm Sci. 2012;47:305–12.
106. Shen Q, Wang Y, Zhang Y. Improvement of colchicine oral bioavailability by incorporating eugenol in the nanoemulsion as an oil excipient and enhancer. Int J Nanomed. 2011;6:1237–43.
107. Choudhury H, Gorain B, Karmakar S, Biswas E, Dey G, Barik R. Improvement of cellular uptake, in vitro antitumor activity and sustained release profile with increased bioavailability from a nanoemulsion platform. Int J Pharm; 460:131–43.
108. Sessa M, Balestrieri ML, Ferrari G, Servillo L, Castaldo D, Onofrio ND. Bioavailability of encapsulated resveratrol into nanoemulsion-based delivery systems. Food Chem. 2014;147:42–50.
109. Jain K, Kumar RS, Sood S, Gowthamarajan K. Enhanced oral bioavailability of atorvastatin via oil-in-water nanoemulsion using aqueous titration method. J Pharm Sci Res. 2013;5(1):18–25.
110. Yu H, Huang Q. Improving the oral bioavailability of curcumin using novel organogel-based nanoemulsions. J Agric Food Chem. 2012;60:5373–9.
111. Ma Y, Li HG, Guan SX. Enhancement of the oral bioavailability of breviscapine by nanoemulsions drug delivery system. Drug Dev Ind Pharm. 2014;12:1–6.
112. Chhabra G, Chuttani K, Mishra AK, Pathak K. Design and development of nanoemulsion drug delivery system of amlodipine besilate for improvement of oral bioavailability. Drug Dev Ind Pharm. 2011;37(8):907–16.
113. Zhao L, Wei Y, Fu J. Nanoemulsion improves the oral bioavailability of baicalin in rats: in vitro and in vivo evaluation. Int J Nanomed. 2013;8:3769–79.
114. Sukanya G, Mantry S, Shireen A. Review on nanoemulsion. Int J Innov Pharm Sci Res. 2013;1(2):192–205.
115. Bruxel F, Cojean S, Bochot A, Teixeira H, Bories C, Loiseau PM, Fattal E. Cationic nanoemulsion as a delivery system for oligonucleotides targeting malarial topoisomerase II. Int J Pharm. 2011;416(2):402–9.
116. Bruxel F, Bochot A, Diel D, Fattal E, Teixeira HF. Adsorption of antisense oligonucleotides targeting malarial topoi-somerase II on cationic nanoemulsions optimized by a full factorial design. Curr Topics Med Chem. 2014;14(9):1161–71.
117. Li X, Xu Y, Chen G, Wei P, Ping Q. PLGA nanoparticles for the oral delivery of 5-fluorouracil using high pressure homogenization—emulsification as the preparation method and in vitro/in vivo studies. Drug Dev Ind Pharm. 2008;34:107–15.
118. Sarmento B, Ribeiro A, Veiga F, Ferreira D, Neufeld R. Oral bioavailability of insulin contained in polysaccharide nanoparticles. Biomacromolecules. 2007;8:3054–60.
119. Bharadwaj V, Ravikumar MNV. Polymeric nanoparticles for oral delivery. New York: Taylor and Francis; 2006.
120. Galindo-Rodriguez SA, Allemann E, Fessi H, Doelker E. Polymeric nanoparticles for oral delivery of drugs and vaccines: a critical evaluation of in vivo studies. Crit Rev Ther Drug Carrier Syst. 2005;22:419–64.
121. Seju U, Kumar A, Sawant KK. Development and evaluation of olanzapineloaded PLGA nanoparticles for nose-to-brain delivery: in vitro and in vivo studies. Acta Biomater. 2011;7:4169–76.
122. Hosseinzadeh H, Atyabi F, Dinarvand R, Ostad SN. Chitosan–pluronic nanoparticles as oral delivery of anticancer gemcitabine: preparation and in vitro study. Int J Nanomed. 2012;7:1851–63.
123. Joshi G, Kumar A, Sawant K. Enhanced bioavailability and intestinal uptake of gemcitabine HCl loaded PLGA nanoparticles after oral delivery. Eur J Pharm Sci. 2014;60:80–9.
124. Suwannateep N, Banlunara W, Wanichweeharumgruang SP, Chiablaem K, Lirdprapamongkol K, Svast J. Mucoadhesive curcumin nanospheres: biological activity adhesion to stomach mucosa and release of curcumin into circulation. J Control Release. 2011;151:176–82.
125. Yang YY, Wang Y, Powell R, Chan P. Polymeric core-shell nanoparticles for therapeutics. Clin Exp Pharmacol Physiol. 2006;33:557–62.
126. Bolmal UB, Manvi FV, Kotha Rajkumar K, Palla SS, Paladugu A, Reddy KR. Recent advances in nanosponges as drug delivery system. Int J Pharm Sci Nanotechnol. 2013;6.
127. Sharma R, Pathak K. Nanosponges: emerging drug delivery system. Pharma Stud. 33–35.
128. Thomas N, Holm R, Mullertz A, Rades T. In vitro and in vivo performance of novel supersaturated selfnanoemulsifying drug delivery systems (super-SNEDDS). J Control Release. 2012;160(1):25–32.
129. Porter CJH, Pouton CW, Cuine JF, Charman WN. Enhancing intestinal drug solubilisation using lipid-based delivery systems. Adv Drug Deliv Rev. 2008;60(6):673–91.
130. Porter CJH, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov. 2007;6:231–48.
131. Nangwade BK, Patel DJ, Udhani RA, Manvi FV. Functions of lipids for enhancement of oral bioavailability of poorly water-soluble drugs. Sci Pharm. 2011;79(4):705–25.
132. Date AA, Desai N, Dixit R, et al. Self-nanoemulsifying drug delivery systems: formulation insights, applications and advances. Nanomed. 2010;5(10):1595–616.
133. Jing-Ling T, Jin S, Zhong-Gui H. Emulsifying drug delivery systems: strategy for improving oral delivery of poorly soluble drugs. Curr Drug Ther. 2007;2:85–93.
134. Patel A, Shelat P, Lalwani A. Development and optimization of solid self-nanoemulsifying drug delivery system (S-SNEDDS) using Scheffe’s design for improvement of oral bioavailability of nelfinavir mesylate. Drug Deliv Transl Res. 2014;4:171–86.
135. Heshmati N, Cheng X, Eisenbrand G, Fricker G. Enhancement of oral bioavailability of e804 by self-nanoemulsifying drug delivery system (SNEDDS) in rats. J Pharm Sci. 2013;102(10):3792–9.
136. Sakloetsakun D, Dünnhaupt S, Barthelmes J, Perera G, Schnürch AB. Combining two technologies: multifunctional polymers and self-nanoemulsifying drug delivery system (SNEDDS) for oral insulin administration. Int J Biol Macromol. 2013;61:363–72.
137. Quan Q, Kim DW, Marasini N, Kim DH, Kim JK, Kim JO. Physicochemical characterization and in vivo evaluation of solid self-nanoemulsifying drug delivery system for oral administration of docetaxel. J Microencapsul. 2013;30(4):307–14.
138. Seo YG, Kim DH, Ramasamy T, Kim JH, Marasini N, Oh YK. Development of docetaxel-loaded solid self-nanoemulsifying drug delivery system (SNEDDS) for enhanced chemotherapeutic effect. Int J Pharm. 2013;452(1–2):412–20.
139. Mahmoud DB, Shukr MH, Bendas ER. In vitro and in vivo evaluation of self-nanoemulsifying drug delivery systems of cilostazol for oral and parenteral administration. Int J Pharm. 2014;476(1–2):60–9.
140. Singh B, Singh R, Bandyopadhyay S, Kapil R, Garg B. Optimized nanoemulsifying systems with enhanced bioavailability of carvedilol. Colloid Surf B. 2013;101:465–74.
141. Bajaj A, Rao MRP, Khole I, Munjapara G. Self emulsifying drug delivery system of cefpodoxime proxetil containing tocopherol polyethylene glycol succinate. Drug Dev Ind Pharm. 2013;39(5):635–45.
142. Janga KY, Jukanti R, Sunkavalli S, Kandadi P, Veerareddy PR. In situ absorption and relative bioavailability studies of zaleplon loaded self-nanoemulsifying powders. J Microencapsul. 2013;30(2):161–72.
143. Kumar SR, Syamala SU, Revathi P, Raghuveer P, Gowthamarajan K. Self nanoemulsifying drug delivery system of olanzapine for enhanced oral bioavailability: in vitro, in vivo characterisation and in vitro -in vivo correlation. J Bioequiv Availab. 2013. doi:10.4172/jbb.1000159.
144. Kamel AO, Mahmoud AA. Enhancement of human oral bioavailability and in vitro antitumor activity of rosuvastatin via spray dried self-nanoemulsifying drug delivery system. J Biomed Nanotechnol. 2013;9(1):26–39.
145. Akhter MH, Ahmad A, Ali J, Mohan G. Formulation and development of CoQ10-loaded s-SNEDDS for enhancement of oral bioavailability. J Pharm Innovat. 2014;9(2):121–31.
146. Jain AK, Thanki K, Jain S. Solidified self-nanoemulsifying formulation for oral delivery of combinatorial therapeutic regimen: part II in vivo pharmacokinetics, antitumor efficacy and hepatotoxicity. Pharm Res. 2014;31(4):946–58.
147. Singh G, Pai RS. Optimized self-nanoemulsifying drug delivery system of atazanavir with enhanced oral bioavailability: in vitro/in vivo characterization. Expert Opin Drug Deliv. 2014;11(7):1023–32.
148. Patel J, Dhingani A, Garala K, Raval M, Sheth N. Quality by design approach for oral bioavailability enhancement of irbesartan by self-nanoemulsifying tablets. Drug Deliv. 2014;21(6):412–35.
149. Zhang Z, Huang J, Jiang S, Liu Z, Gu W, Yu H, Li Y. A high-drug-loading self-assembled nanoemulsion enhances the oral absorption of probucol in rats. J Pharm Sci. 2013;102(4):1301–6.
150. Zhang J, Peng Q, Shi S, Gong T, Zhang Z. Preparation, characterization, and in vivo evaluation of a self-nanoemulsifying drug delivery system (SNEDDS) loaded with morin–phospholipid complex. Int J Nanomed. 2011;6:3405–14.
151. Patel J, Patel A, Raval M, Sheth N. Formulation and development of a self-nanoemulsifying drug delivery system of irbesartan. J Adv Pharm Technol Res. 2011;2(1):9–16.
152. Ruan J, Liu J, Zhu D, Hao X, Zhang Z. Preparation and evaluation of self-nanoemulsified drug delivery systems (SNEDDSs) of matrine based on drug–phospholipid complex technique. Int J Pharm. 2010;386(1–2):282–90.
153. Larsen AT, Ogbonna AG, Polentarutti B, Barker RA, Phillips AR, Rmaileh AR. Oral bioavailability of cinnarizine in dogs: relation to SNEDDS particle size, drug solubility and in vitro precipitation. Eur J Pharm Sci. 2013;48:339–50.
154. Larsen AT, Ogbonna AB, Rmaileh AR, Østergaard A, Müllertz J. SNEDDS containing poorly water soluble cinnarizine; development and in vitro characterization of dispersion, digestion and solubilization. Pharmaceutics. 2012;4:641–65.
155. Gursoy RN, Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother. 2004;58(3):173–82.
156. Khan AW, Kotta S, Ansari SH. Potentials and challenges in selfnanoemulsifying drug delivery systems. Expert Opin Drug Deliv. 2012;9(10):1305–17.
157. Zhao Y, Wang C, Chow AHL, Ren K, Gong T, Zhang Z, Zheng Y. Self-nanoemulsifying drug delivery system (SNEDDS) for oral delivery of zedoary essential oil: formulation and bioavailability studies. Int J Pharm. 2010;383:170–7.
158. Dabhi MR, Limbani MD, Sheth NR. Preparation and in vivo evaluation of self-nanoemulsifying drug delivery system (SNEDDS) containing ezetimibe. Curr Nanosci. 2011;7(4):616.
159. Bandyopadhyay S, Katare OP, Singh B. Development of optimized supersaturable self-nanoemulsifying systems of ezetimibe: effect of polymersand efflux transporters. Expert Opin Drug Deliv. 2014;11(4):479–92.
160. Tran T, Guo Y, Song D, Bruno RS, Lu XI. Quercetin-containing self-nanoemulsifying drug delivery system for improving oral bioavailability. J Pharm Sci. 2014;103:840–52.
161. Tang B, Cheng G, Gu JC, Xu CH. Development of solid self-emulsifying drug delivery systems: preparation techniques and dosage forms. Drug Discov Today. 2008;13(13–14):606–12.
162. Yi T, Wan J, Xu H, Yang X. A new solid self-microemulsifying formulation prepared by spray-drying to improve the oral bioavailability of poorly water soluble drugs. Eur J Pharm Biopharm. 2008;70(2):439–44.
163. Wang Z, Sun J, Wang Y, Liu X, Liu Y, Fu Q, et al. Solid self-emulsifying nitrendipine pellets: preparation and in vitro/in vivo evaluation. Int J Pharm. 2010;383(1–2):1–6.
164. Abbaspour M, Jalayer N, Makhmalzadeh BS. Development and evaluation of a solid self-nanoemulsifying drug delivery system for loratadin by extrusion-spheronization. Adv Pharm Bull. 2014;4(2):113–9.
165. Beg S, Jena SS, Patra CN, Rizwan M, Swain S, Sruti J, et al. Development of solid self nanoemulsifying granules (SSNEGs) of ondansetron hydrochloride with enhanced bioavailability potential. Colloid Surf B. 2013;101:414–23.
166. Piao ZZ, Choe JS, Oh KT, Rhee YS, Lee BJ. Formulation and in vivo human bioavailability of dissolving tablets containing a self-nanoemulsifying itraconazole solid dispersion without precipitation in simulated gastrointestinal fluid. Eur J Pharm Sci. 2014;51:67–74.
167. Shono Y, Jantratid E, Dressman JB. Precipitation in the small intestine may play a more important role in the in vivo performance of poorly soluble weak bases in the fasted state: case example nelfinavir. Eur J Pharm Biopharm. 2011;79:349–56.
168. Attama AA. SLN, NLC, LDC: state of the art in drug and active delivery. Recent Pat Drug Deliv Formul. 2011;5:178–87.
169. Muchow M, Maincent P, Müller RH, Keck CM. Production and characterization of testosterone undecanoate-loaded NLC for oral bioavailability enhancement. Drug Dev Ind Pharm. 2011;37(1):8–14.
170. Varshosaz J, Minayian M, Moazen E. Enhancement of oral bioavailability of pentoxifylline by solid lipid nanoparticles. J Liposome Res. 2010;20(2):115–23.
171. Hu LD, Xing Q, Meng J, Shang C. Preparation and enhanced oral bioavailability of cryptotanshinone-loaded solid lipid nanoparticles. AAPS PharmSciTech. 2010;11(2):582–7.
172. Varshosaz J, Tabbakhian M, Mohammadi MY. Formulation and optimization of solid lipid nanoparticles of buspirone HCl for enhancement of its oral bioavailability. J Liposome Res. 2010;20(4):286–96.
173. Zhuang CY, Li N, Wang M, Zhang XN, Peng JJ, Pan WS. Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability. Int J Pharm; 394:179–85.
174. Ravi PR, Vats R, Dalal V, Murthy AN. A hybrid design to optimize preparation of lopinavir loaded solid lipid nanoparticles and comparative pharmacokinetic evaluation with marketed lopinavir/ritonavir coformulation. J Pharm Pharmacol. 2014;66(7):912–26.
175. Zhang Z, Bu H, Gao Z, Huang Y, Gao F, Li Y. The characteristics and mechanism of simvastatin loaded lipid nanoparticles to increase oral bioavailability in rats. Int J Pharm. 2010;394(1–2):147–53.
176. Beloqui A, Solinís MA, Rieux A, Préat V, Gascón AR. Dextran protamine coated nanostructured lipid carriers as mucus-penetrating nanoparticles for lipophilic drugs. Int J Pharm. 2014;468:105–11.
177. Thulasi Ram D, Debnath S, Niranjan Babu M, Chakradhar Nath T, Thejeswi B. A review on solid lipid nanoparticles. Res J Pharm. Technol. 2012;5(11):1359–68.
178. ®) for oral drug delivery. Drug Dev Ind Pharm. 2008;34:1394–405.
179. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery—a review of the state of the art. Eur J Pharm Biopharm. 2000;50:161–77.
180. Pathak P, Keshri L, Shah M. Lipid nanocarriers: influence of lipids on product development and pharmacokinetics. Crit Rev Ther Drug. 2011;28(4):357–93.
181. Tarr BD, Yalkowsky SH. Enhanced intestinal absorption of cyclosporine in rats through the reduction of emulsion droplet size. Pharm Res. 1989;6(1):40–3.
182. Kreuter J. Peroral administration of nanoparticles. Adv Drug Deliv Rev. 1991;7:71–86.
183. Manjunath K, Venkateswarlu V. Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Control Release. 2005;107:215–28.
184. Fricker G, Wendel A, Blume A, Zirkel J, Rebmann H, Setzer C, et al. Phospholipids and lipid-based formulations in oral drug delivery. Pharm Res. 2010;27:1469–86.
185. Olbrich C, Gebner A, Kayser O, Muller RH. Lipid-drug conjugate (LDC) nanoparticles as a novel carrier system for the hydrophilic antitrypanosomal drug diminazenediaceturate. J Drug Target. 2002;10:387–96.
186. Muller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev. 2002;54:S131–55.
187. Xie S, Pan B, Wang M, Zhu L, Wang F, Dong Z, et al. Formulation, characterization and pharmacokinetics of praziquantel-loaded hydrogenated castor oil solid lipid nanoparticles. Nanomed (Lond). 2010;5(5):693–701.
188. Luo CF, Yuan M, Chen MS, Liu SM, Zhu L, Huang BY, et al. Pharmacokinetics, tissue distribution and relative bioavailability of puerarin solid lipid nanoparticles following oral administration. Int J Pharm. 2011;410:138–44.
189. Alex AMR, Chacko AJ, Jose S, Souto EB. Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting. Eur J Pharm Sci. 2011;42(1–2):11–8.
190. Montenegro L, Campisi A, Sarpietro MG, Carbone C, Acquaviva R, Raciti G, et al. In vitro evaluation of idebenone-loaded solid lipid nanoparticles for drug delivery to the brain. Drug Dev Ind Pharm. 2011;37(6):737–46.
191. Zhang X, Qiao H, Zhang T, Shi Y, Ni J. Enhancement of gastrointestinal absorption of isoliquiritigenin by nanostructured lipid carrier. Adv Powder Technol. 2014;25(3):1060–8.
192. Patil-Gadhe A, Pokharkar V. Montelukast-loaded nanostructured lipid carriers: part I oral bioavailability improvement. Eur J Pharm Biopharm. 2014;88(1):160–8.
193. Muchow M, Maincent P, Müller RH, Keck CM. Testosterone undecanoate—increase of oral bioavailability by nanostructured lipid carriers (NLC). J Pharm Technol Drug Res. 2010. doi:10.7243/2050-120X-2-4.
194. Shangguan M, Lu Y, Qi J, Han J, Tian Z, Xie Y, et al. Binary lipids-based nanostructured lipid carriers for improved oral bioavailability of silymarin. J Biomater Appl. 2014;28(6):887–96.
195. Sun M, Wang S, Nie S, Zhang J. Enhanced oral bioavailability of quercetin by nanostructured lipid carriers. FASEB J. 2014;28(1) (supplement 1044.24).
196. Liu L, Tang Y, Gao C, Li Y, Chen S, Xiong T, et al. Characterization and biodistribution in vivo of quercetin-loaded cationic nanostructured lipid carriers. Colloid Surf B. 2014;115:125–31.
197. Madaan K, Kumar S, Poonia N, Lather V, Pandita D. Dendrimers in drug delivery and targeting: drug-dendrimer interactions and toxicity issues. J Pharm Bioallied Sci. 2014;6(3):139–50.
198. Cheng Y, Xu Z, Ma M, Xu T. Dendrimers as drug carriers: applications in different routes of drug administration. J Pharm Sci. 2008;97(1):123–43.
199. Menjoge AR, Rinderknecht AL, Navath RS, Faridnia M, Kim CJ, Romero RJ. Controlled Release. 2011;149:21.
200. Kaminskas LM, McLeod VM, Kelly BD, Sberna G, Boyd BJ, Williamson M. A comparison of changes to doxorubicin pharmacokinetics, antitumor activity, and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systems. Nanomed Nanotechnol Biol Med. 2012;8:103–11.
201. Sadekar S, H. Ghandehari H. Transepithelial transport and toxicity of PAMAM dendrimers: implications for oral. Adv Drug Deliv Rev. 2014;64:571–88.
202. Patel J, Garala K, Dharamsi A. Solubility of aceclofenac in polyamidoamine dendrimer solutions. Int J Pharm Investig. 2011;1(3):135–8.
203. Patel RM, Patel HN, Gajjar DG, Patel PM. Enhanced solubility of non-steroidal anti-inflammatory drugs by hydroxyl terminated S-triazine based dendrimers. Asian J Pharm Clin Res. 2014;7:156–61.
204. Teow HM, Zhou Z, Najlah M, Yusof SR, Abbott NJ, D’Emanuele A. Delivery of paclitaxel across cellular barriers using a dendrimer-based nanocarrier. Int J Pharm. 2012. doi:10.1016/j.ijpharm.2012.10.024.
205. Abufazali R. Carbon nanotubes: a promising approach for drug delivery. Iranian J Pharm Res. 2010;9(1):1–3.
206. Sui L, Yang T, Gao P, Ai M, Pingting Wang PA, Zhenzhen WuZ, et al. Incorporation of cisplatin into PEG-wrapped ultrapurified large-inner- diameter MWCNTs for enhanced loading efficiency and release profile. Int J Pharm. 2014;471:157–65.
207. Tan JM, Karthivashan G, Arulselvan P, Fakurazi S, Hussein MZ. Characterization and in vitro sustained release of silibinin from pH responsive carbon nanotube-based drug delivery system. J Nanomater. 2014. doi:10.1155/2014/439873.
208. Hilder TA, Hill JM. Modeling the loading and unloading of drugs into nanotubes. Small. 2009. doi:10.1002/smll.200800321.
209. Giorgia P. Crucial functionalizations of carbon nanotubes for improved drug delivery: a valuable option. Pharm Res. 2009;26(4):746–69.
210. Prajapati VK, Awasthi K, Gautam S, et al. Targeted killing of Leishmania donovani in vivo and in vitro with amphotericin B attached to functionalized carbon nanotubes. J Antimicrob Chemother. 2010;66:874–9.
211. Prajapati VK, Awasthi K, Yadav TP, Srivastava ON, Sundar S. An oral formulation of amphotericin B attached to functionalized carbon nanotubes is an effective treatment for experimental visceral leishmaniasis. J Infect Dis. 2012;205(2):333–6.
212. Foldvari M, Bagonluri M. Carbon nanotubes as functional excipients for nanomedicines: I. Pharmaceutical properties. Nanomed Nanotechnol Biol Med. 2008;4:173–82.
213. Foldvari M, Bagonluri M. Carbon nanotubes as functional excipients for nanomedicines: II. Drug delivery and biocompatibility issues. Nanomed Nanotechnol Biol Med. 2008;4:13–200.
214. Ye S, Jiang Y, Zhang H. Modulation of apoptotic pathways of macrophages by surface-functionalized multi-walled carbon nanotubes. PLoS One. 2013;8.
215. Ito Y, Venkatesan N, Hirako N, Sugioka N, Takada K. Effect of fiber length of carbon nanotubes on the absorption of erythropoietin from rat small intestine. Int J Pharm. 2008;337:357–60.
216. Lee Y, Geckeler KE. Carbon nanotubes in the biological interphase: the relevance of noncovalence. Adv Mater. 2010;22(36):4076–83.
217. Fisher C, Rider AE, Han ZJ, Kumar S, Levchenko I, Ostrikov K. Applications and nanotoxicity of carbon nanotubes and graphene in biomedicine. J Nanomater. 2012. doi:10.1155/2012/315185.
218. Kostarelos K, Bianco A, Lacerda L, et al. Translocation mechanisms of chemically functionalised carbon nanotubes across plasma membranes. Biomaterials. 2012;33(11):3334–43.
219. Zhao F, Zhao Y, Liu Y, Chang X, Chen C, Zhao Y. Cellular uptake, intracellular trafficking, and cytotoxicity of nanomaterials. Small. 2011;7(10):1322–37.
220. Jones MC, Leroux JC. Polymeric micelles: a new generation of colloidal drug carriers. Eur J Pharm Biopharm. 1999;48:101–11.
221. Kwon GS, Okano T. Polymeric micelles as new drug carriers. Adv Drug Deliv Rev. 1996;21:107–16.
222. Riess G. Micellization of block copolymers. Prog Polym Sci. 2003;28:1107–70.
223. Xu W, Ling P, Zhang T. Polymeric micelles, a promising drug delivery system to enhance bioavailability of poorly water-soluble drugs. J Drug Deliv. 2013. doi:10.1155/2013/340315.
224. Kabanov AV, Batrakova EV, Alakhov EY. Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery. J Control Release. 2002;82(2–3):189–212.
225. Bae Y, Kataoka K. Intelligent polymeric micelles from functional poly(ethylene glycol)-poly(amino acid) block copolymers. Adv Drug Deliv Rev. 2009;61(10):768–84.
226. Meier MAR, Aerts SNH, Staal BBP, Rasa M, Schubert US. PEO-b-PCL block copolymers: synthesis, detailed characterization, and selected micellar drug encapsulation behavior. Macromol Rapid Commun. 2005;26(24):1918–24.
227. Ruan G, Feng SS. Preparation and characterization of poly(lactic acid)-poly(ethylene glycol)-poly(lactic acid) (PLA-PEG-PLA) microspheres for controlled release of paclitaxel. Biomaterials. 2003;24(27):5037–44.
228. Taek GK, Lee H, Jang Y, Tae GP. Controlled release of paclitaxel from heparinized metal stent fabricated by layer-by-layer assembly of polylysine and hyaluronic acid-g-poly(lactic-co-glycolic acid) micelles encapsulating paclitaxel. Biomacromolecules. 2009;10:1532–9.
229. Lee H, Ahn CH, Park TG. Poly[lactic-co-(glycolic acid)]-grafted hyaluronic acid copolymer micelle nanoparticles for target-specific delivery of doxorubicin. Macromol Biosci. 2009;9:336–42.
230. Benahmed A, Ranger M, Leroux J. Novel polymeric micelles based on the amphiphilic diblock copolymer poly(N-vinyl-2-pyrrolidone)-block-poly(d, l lactide). Pharm Res. 2001;18:323–38.
231. Inoue T, Chen G, Nakamae K, Hoffman AS. An AB block copolymer of oligo(methyl methacrylate) and poly(acrylic acid) for micellar delivery of hydrophobic drags. J Control Release. 1998;51:221–9.
232. Attia ABE, Ong ZY, Hedrick JL, Phin Peng Lee PP, Pui Lai Rachel EE. Mixed micelles self-assembled from block copolymers for drug delivery. Curr Opin Colloid Interface Sci. 2011;16:182–94.
233. Adams ML, Lavasanifar A, Kwon GS. Amphiphilic block copolymers for drug delivery. J Pharm Sci. 2003;92:1343–55.
234. Rieux A, Fievez V, Garinot M, Schneider YM, Préat Y. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release. 2006;116:1–27.
235. Pierri E, Avgoustakis K. Poly(lactide)-poly(ethylene glycol) micelles as a carrier for griseofulvin. J Biomed Mater Res A. 2005;75:639–47.
236. Kim MS, Lee DS. In vitro degradability and stability of hydrophobically modified pH-sensitive micelles using MPEG-grafted poly(B-amino ester) for efficient encapsulation of paclitaxel. J Appl Polym Sci. doi:10.1002/app.32685.
237. Lee I, Park M, Kim Y, Hwang O, Khang G, Lee D. Ketal containing amphiphilic block copolymer micelles as pH-sensitive drug carriers. Int J Pharm. 2013;448(1):259–66.
238. Wang F, Zhang D, Zhang Q, Chen Y, Zheng D, Hao L, et al. Synergistic effect of folate-mediated targeting and verapamil-mediated P-gp inhibition with paclitaxel–polymer micelles to overcome multi-drug resistance. Biomaterials. 2011;32(35):9444–56.
239. Heffeter P, Riabtseva A, Senkiv Y, Kowol CR, Körner W, Jungwith U. Nanoformulation improves activity of the (pre)clinical anticancer ruthenium complex KP1019. J Biomed Nanotechnol. 2014;10(5):877–84.
240. Sulfikkarali N, Krishnakumar N, Manoharan S, Nirmal RM. Chemopreventive efficacy of naringenin-loaded nanoparticles in 7,12-dimethylbenz(a)anthracene induced experimental oral carcinogenesis. Pathol Oncol Res. 2013;19(2):287–96.
241. Rodríguez GRR, Alonso MK, Torres D. Poly-l-asparagine nanocapsules as anticancer drug delivery vehicles. Eur J Pharm Biopharm. 2013;85(3)part A:481–87.
242. Kanwar JR, Mahidhara G, Kanwar RK. Novel alginate-enclosed chitosan-calcium phosphate-loaded iron-saturated bovine lactoferrin nanocarriers for oral delivery in colon cancer therapy. Nanomedicine (Lond). 2012;7(10):1521–50.
243. Yao HJ, Ju RJ, Wang XX, Zhang Y, Li RJ, Yu Y, et al. The antitumor efficacy of functional paclitaxel nanomicelles in treating resistant breast cancers by oral delivery. Biomaterials. 2011;32(12):3285–302.
244. Sagnella SM, Gong X, Moghaddam MJ, Conn CE, Kimpton K, Waddington LJ, et al. Nanostructured nanoparticles of self-assembled lipid pro-drugs as a route to improved chemotherapeutic agents. Nanoscale. 2011;3(3):919–24.
245. Liu X, Huang H, Wang J, Wang C, Wang M, Zhang B, et al. Dendrimers-delivered short hairpin RNA targeting hTERT inhibits oral cancer cell growth in vitro and in vivo. Biochem Pharmacol. 2011;82(1):17–23.
246. Jain A, Agarwal A, Majumder S, Lariya N, Khaya A, Agrawal H, et al. Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug. J Control Release. 2010;148(3):359–67.
247. Yassin AEB, Anwer MK, Mowafy HA, Bagory IME, Bayomi MA, Alsarra IA. Optimization of 5-fluorouracil solid-lipid nanoparticles: a preliminary study to treat colon cancer. Int J Med Sci. 2010;7(6):398–408.
248. Mei L, Zhang Z, Zhao L, Huang L, Yang XL, Tang J, Feng SS. Pharmaceutical nanotechnology for oral delivery of anticancer drugs. Adv Drug Deliv Rev. 2013;65:880–90.
249. Maynard AD, Baron PA, Foley M, Shvedova AA, Kisin ER, Castranova V. Exposure to carbon nanotube material: aerosol release during the handling of unrefined single-walled carbon nanotube material. J Toxicol Environ Health Part A. 2004;67:87–107.
250. Han SG, Andrews R, Gairola CG. Acute pulmonary response of mice to multi-wall carbon nanotubes. Inhalation Toxicol. 2010;22(4):340–7.
251. Porter DW, Hubbs AF, Mercer RR, Wu N, Wolfarth MG, Sriram K, et al. Mouse pulmonary dose- and time course-responses induced by exposure to multi-walled carbon nanotubes. Toxicology. 2010;269(2–3):136–47.
252. Wolfarth MG, McKinney W, Chen BT, Castranova V, Porter DW. Acute pulmonary responses to MWCNT inhalation. Toxicologist. 2011;120:A53.
253. Reddy AR, Reddy YN, Krishna DR, Himabindu V. Multiwall carbon nanotubes induce oxidative stress and cytotoxicity in human embryonic kidney (HEK293) cells. Toxicology. 2010;272(1–3):11–6.
254. Lam CW, James JT, McCluskey R, Hunter RL. Pulmonary toxicity of single-wall carbon nanotubes in mice 7 and 90 days after intratracheal instillation. Toxicol Sci. 2004;77:126–34.
255. Shvedova AA, Kisin ER, Mercer R, Murray AR, Johnson VJ, Potapovich AF, et al. Unusual inflammatoryand fibrogenic pulmonary, response to single-walled carbon nanotubes in mice. Am J Physiol Lung Cell Mol Physiol. 2005;289:L698–708.
256. Warheit DB, Laurence BR, Reed KL, Roach DH, Reynolds GA, Webb TR. Comparative pulmonary toxicity assessment of single-wall carbon nanotubes in rats. Toxicol Sci. 2004;77:117–25.
257. Liao L, Zhang M, Liu H, Gong T, Sun X. Subchronic toxicity and immunotoxicity of MeO-PEG-poly(d, l-lactic-co- glycolic acid)-PEG-OMe triblock copolymer nanoparticles delivered intravenously into rats. Nanotechnology. 2014;25(24):245.
258. Zhao B, Wang XQ, Wang XY, Wu HN, Zhang Q. Nanotoxicity comparison of four amphiphilic polymeric micelles with similar hydrophilic or hydrophobic structure. Particle Fibre Toxicol. 2013;10(1):47.
259. Thiagarajan G, Greish K, Ghandehari H. Charge affects the oral toxicity of poly(amido amine) dendrimers. Eur J Pharm Biopharm. 2013;84(2):330–4.
260. Onoue S, Yamada S, Chan HK. Nanodrugs: pharmacokinetics and safety. Int J Nanomed. 2014;9:1025–37.
261. Nagender RP, Pena-Mendez EM, Havel J. Gold and nano-gold in medicine: overview, toxicology and perspectives. J Appl Biomed. 2009;7:75–91.
262. Parrott N, Lave T. Applications of physiologically based absorption models in drug discovery and development. Mol Pharm. 2008;5(5):760–75.
263. Gu CH, Rao D, Gandhi RB, Hilden J, Raghavan K. Using a novel multicompartment dissolution system to predict the effect of gastric pH on the oral absorption of weak bases with poor intrinsic solubility. J Pharm Sci. 2005;94(1):199–208.
264. Gupta V, Doshi N, Mitragotri S. Permeation of insulin, calcitonin and exenatide across Caco-2 monolayers: measurement using a rapid, 3-day system. PLOS One. 2013;8(2):1–19.
265. Wu YF, Liu H, Ni JM. Advances in parallel artificial membrane permeability assay and its applications. Yao Xue Xue Bao. 2011;46(8):890–5.
266. Nielsen PE, Avdeef A. PAMPA—a drug absorption in vitro model 8. Apparent filter porosity and the unstirred water layer. Eur J Pharm Sci. 2004;22:33–41.
267. Kansy M, Avdeef A, Fischer H. Advances in screening for membrane permeability: high-resolution PAMPA for medicinal chemists. DDT Technol. 2004;1:349–55.
268. Tavelin S, Taipalensuu J, Hallbook F, Vellonen KS, Moore V, Artursson P. An improved cell culture model based on 2/4/A1 cell monolayers for studies of intestinal drug transport: characterization of transport routes. Pharm Res. 2003;20:373–81.
269. Tavelin S, Taipalensuu J, Soderberg L, Morrison R, Chong S, Artursson P. Prediction of the oral absorption of low-permeability drugs using small intestine-like 2/4/A1 cell monolayers. Pharm Res. 2003;20:397–405.
270. Bryan WJ. Enhancement & controlled release as a synergistic tools. Drug Deliv Technol. 2002;2(6).
271. Beg S, Swain S, Rizwan M. Irfanuddin, Malini DS. Bioavailability enhancement strategies: basics, formulation approaches and regulatory considerations. Curr Drug Deliv. 2011;8(6):1–12.
272. Lappin G, Garner R. The use of accelerator mass spectrometry to obtain early human ADME/PK data. Expert Opin Drug Metabol. Toxicol. 2005;1(1):23–31.
273. Bonnafous D, Cav G, Dembri A, Binay SL, Ponchel G, GPE. Oral formulations of chemotherapeutic agents. 2010;WO 2010015688 A1.
274. Sung HW, Kiran Sonaje K, Tu H. Pharmaceutical composition of nanoparticles for protein drug delivery. 2012;US20120003306 A1.
275. Schobel AM, Myers, Garry ML, Joseph KK, Thomas R, Jan M, Justin NW. Nanoparticle film delivery systems. 2011;WO/2011/156711.
276. Park TG, Kim HR, Kim IK. LDL-like cationic nanoparticles for delivering nucleic acid gene, method for preparing thereof and method for delivering nucleic acid gene using the same. 2010;US 20100297242A1.
277. Radovic-Moreno AF, Zhang L, Langer RS, Farokhzad OC. Polymer-encapsulated reverse micelles. 2010;US20100196482 A1.
278. Rios MDL, Oh KL. Self-assembling nanoparticle drug delivery system. 2011;US7964196 B2.
279. Bronich TK, Kabanov AV. Synthesizing an amphiphilic block polymer micelle having ionically-charged polymeric segments and nonionically-charged polymeric segments; neutralizing under conditions that allow for self-assembly of polymer micelles; crosslinking; removing the moieties of opposite charge; drug delivery; stability. 2013;US 8415400 B2.
280. Baker JR, Zhang Y. Hydroxyl-terminated dendrimers. 2011;WO 2011053618A2.
281. Matuschek M, Ernst A, Köpsel C, Jager MB, Kleber A, Krohn M, et al. Use of water-dispersible carotenoid nanoparticles as taste modulators, taste modulators containing water-dispersible carotenoid nanoparticles, and method for test modulation. 2010;US20100028444 A1.
282. Porter V, Morgan A, Prencipe M. Oral care composition. 2013;US20130017240.
283. Sahoo SK, Mohanty C. Novel water soluble curcumin loaded nanoparticulate system for cancer therapy. 2011;WO Patent 2011101859 A1.